Verition Fund Management’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-115,400
Closed -$13.4M 2716
2021
Q4
$13.4M Sell
115,400
-7,450
-6% -$877K 0.1% 127
2021
Q3
$14.8M Buy
122,850
+17,850
+17% +$2.08M 0.13% 112
2021
Q2
$12.6M Sell
105,000
-73,050
-41% -$8.01M 0.11% 108
2021
Q1
$17.7M Buy
178,050
+44,100
+33% +$4.43M 0.2% 71
2020
Q4
$13.4M Buy
+133,950
New +$14.2M 0.12% 111

Other funds holding AZN

Verition Fund Management's AZN Position: Q2 2026 in Review

Verition Fund Management opened a new position in AstraZeneca (AZN) in Q2 2026: 12,704 shares worth $2.41M. The stake represents 0.01% of the portfolio and ranks #1016 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in AZN as recently as Q4 2025.

Verition Fund Management first reported a position in AZN in Q2 2013 and has held it in 24 quarters since. The position peaked at $160M in Q3 2021. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Verition Fund Management held 12,704 shares of AstraZeneca worth $2.41M as of Q2 2026.
  • AstraZeneca was a new Verition Fund Management position in Q2 2026.
  • AstraZeneca made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1016 holding.
  • Verition Fund Management first reported a position in AstraZeneca in Q2 2013 and has held it in 24 quarters since.
  • Verition Fund Management's AstraZeneca position peaked at $160M in Q3 2021.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.